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A B S T R A C T
Psoroptic mange is an important parasitic disease that mainly affects beef cattle producing marked economic
losses. Ivermectin (IVM) is considered one of the most effective treatments against psoroptic mange and is used
worldwide to control both endo and ectoparasites in different species. The current work assessed the relationship
between pharmacokinetic behavior of IVM and its efficacy against Psoroptes ovis after the subcutaneous ad-
ministration of two commercial formulations in a cattle feedlot. Aberdeen Angus and Hereford steers were
selected based on the presence of active mite infestations. Animals were allocated into 4 experimental groups
and treated with a single (day 0) or repeated subcutaneous injection (days 0 and 7) of one of two commercial
formulations of IVM (1%) at 0.2 mg/kg. Blood and skin samples were taken from 8 randomly selected animals of
each experimental group to measure IVM concentrations by HPLC. Skin scrapings were also collected from six
different sites in each animal, mites were counted and ranked based on a density score. Equivalent plasma
concentrations of IVM were measured after the administration of IVM formulations under study. The repeated
administration of both IVM formulations at day 0 and 7 accounted for a greater plasma drug availability
compared with the single administration (P < 0.05). IVM was well distributed from the plasma to the skin
without significant differences between both IVM formulations. There was a positive correlation between IVM
concentrations in skin and plasma (r: 0.73 P < 0.0001). The mean ratios between IVM availabililty (measured
as AUC) in the skin and in plasma were between 1.2 and 2.1. The repeated administration of IVM increased
significantly the IVM concentrations in the skin of areas affected by mange. IVM failed to obtain a parasitological
cure in the different groups affected by mange. The failure was observed with both formulations administeredat
single or repeated doses. Based on the number of animals cured, the range of efficacy was between 0% on day 7
and 60% on day 28 post-treatment. No significant differences in the P. ovis density scores were observed after the
IVM treatment at single or repeated doses. Additional studies are needed to confirm the presence of resistant
strains of P.ovis and to establish the appropriate measures to control these parasitic infestations in feedlot cattle.
1. Introduction
Psoroptic mange caused by Psoroptes ovis is the most common type
of mange in cattle and sheep in many temperate regions of the world.
The disease frequently follows a severe clinical course and may lead to
important losses from mortality and impaired productivity (Eddi et al.,
2002). Acaricidal dips and injectable macrocyclic lactones are the main
pharmacological tools recommended for controlling psoroptic scabies
in cattle (Wright, 1990). Since 1980, ivermectin (IVM) has been con-
sidered one of the most effective treatments against psoroptic mange
and is used worldwide to control endo and ectoparasites in different
species (Campbell, 2012). The high lipophilicity of IVM and its phar-
macokinetic profile support its activity against mites. After the sub-
cutaneous treatment of cattle, IVM is extensively distributed from the
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bloodstream to different target tissues including the different layers of
the skin (Lifschitz et al., 2000).
Different factors may increase the risk of development of psoroptic
mange: high cattle concentration, short sunlight period, cold and humid
climate, low food availability and the presence of internal parasites
(Eddi et al., 2002). However, in endemic areas of South America, the
frequent use of IVM has reduced the number of mange outbreaks. Al-
though mite eggs are not susceptible to the different antiparasitic drugs,
the persistence of IVM in the animals leads to the death of newly born
larvae and the elimination of the P. ovis infestation following a single
injection of 0.2 mg/kg (Guillot and Meleney, 1982; Lonneux et al.,
1997).
After several years of intensive use, resistance to IVM is widespread
in nematodes from small ruminants and cattle (Kaplan and
Vidyashankar, 2012; Cristel et al., 2017). However, information on the
resistance of P. ovis to IVM is scarce. A differential efficacy of two
formulations of IVM has been reported in a cattle feedlot (Genchi et al.,
2008). Additionally, two treatments with a generic IVM preparation
given at a 14-day interval failed to cure Belgian blue cattle infected
with P. ovis (Lekimme et al., 2010), although the presence of resistant
mites could not be established. The current work assessed the re-
lationship between the IVM pharmacokinetic behavior and its efficacy
against P. ovis infestations following the subcutaneous administration of
two commercial formulations in a cattle feedlot.
2. Materials and methods
2.1. Field trial and animals
The current study was carried out in a commercial cattle feedlot
farm in which 10,000 animals are usually fattened. This feedlot is lo-
cated in Tandil, Buenos Aires Province, Argentina, and had a history of
previous failure of IVM treatment against mange infestations, based on
empirical observations. From a herd of 150 Aberdeen Angus and
Hereford steers, 40 animals (388 ± 53 kg) were selected based on the
presence of active mite infestations. All steers with mange included in
the study were ear tagged. Animal procedures were performed ac-
cording to the Animal Welfare Policy (act 12/2013) of the Faculty of
Veterinary Medicine, Universidad Nacional del Centro de la Provincia
de Buenos Aires (UNCPBA), Tandil, Argentina (http://www.vet.unicen.
edu.ar).
2.2. Experimental design, treatments and sampling
Experimental steers were assigned to one of four experimental
groups using a table of random numbers (10 animals in each group).
The day of allocation was designated as Day 0. Animals were in-
dividually weighed and subcutaneously treated with IVM as follows:
GROUP 1: Animals received IVM (IVOMEC®, Boehringer-Ingelheim,
Formulation A) at a dose rate of 0.2mg/kg on Day 0.
GROUP 2: Animals received two injections of IVM (IVOMEC®,
Boehringer-Ingelheim, Formulation A) at a dose rate of 0.2 mg/kg on
Day 0 and Day 7, respectively.
GROUP 3: Animals received IVM (Bagomectina, Biogenesis-Bago®,
Formulation B) at a dose rate of 0.2 mg/kg on Day 0.
GROUP 4: Animals received two injections of IVM (Biogenesis-
Bago®, Formulation B) at a dose rate of 0.2 mg/kg on Day 0 and Day 7,
respectively.
Following treatments, the experimental groups were separated
outdoors in different pens in order to avoid contact among them and
with other animals in the feedlot. Water was supplied ad libitum and
animals were offered a mixed ration given twice a day. The health of
the animals was assessed at regular intervals throughout the study. An
untreated control group was not included in the study to avoid potential
and serious animal welfare issues.
2.2.1. Pharmacological assay
Blood and skin samples were taken from 8 randomly selected ani-
mals of each experimental group. Blood samples (7 mL) from the ju-
gular vein were collected from each animal by means of heparinised
Vacutainer® tubes (Becton Dickinson, NJ, USA) prior to treatment and
at 7, 14, 21 and 28 days post-treatment. Skin samples were also col-
lected from the areas affected by mange prior to treatment and at 7, 14,
21 and 28 days post-treatment and kept in labeled vials. Blood samples
were centrifuged at 2000× g for 20min and the recovered plasma was
kept in labeled vials. Plasma and skin samples were stored at −20 °C
until analysis by high-performance liquid chromatography (HPLC) to
determine IVM concentrations.
2.2.2. Parasitological observations
On days 0, 7, 14, 21 and 28 post-treatment, skin scrapings were
collected from the periphery of active lesions of individual animals. At
each sampling time, six different sites measuring approximately 6 cm2
were scraped on each animal using a sharp spoon. Mites found on each
animal were counted in the Laboratory within 8 h after sampling using
a stereomicroscope and ranked according to the following density
score: 0: no mites; 1: 1–5 mites; 2: 6–25 mites; 3: 26–50 mites; 4:
51–100 mites; 5:> 100 mites.
2.3. Analytical procedures
2.3.1. IVM chemical extraction and chromatographic conditions
IVM concentrations in plasma and skin samples were measured
following an adaptation of the technique described by Lifschitz et al.
(1999, 2000). Briefly, a 0.25mL aliquot of plasma sample or 0.25 g of
skin were combined with 20 ng of the internal standard compound
(moxidectin) and then mixed with 1mL of acetonitrile. After mixing for
20min (samples were sonicated in an ultrasonic bath for 10min.
(Transsonic 570/H, Laboratory Line Instruments Inc., Melrose Park, IL,
USA). The solvent-sample mixture was centrifuged at 2000× g during
15min and the supernatant was manually transferred into a tube and
concentrated to dryness under a stream of nitrogen. The derivatization
of IVM was done following the technique described by De Montigny
et al. (1990). IVM concentrations in plasma and skin were determined
by HPLC using a Shimadzu 10A HPLC system with fluorescence de-
tection reading at 365 nm (excitation) and 475 nm (emission wave-
length). Calibration curves were prepared in the range between 0.2 and
100 ng/mL or g. Correlation coefficients (r) and coefficient of variations
(CV) were calculated. The linear regression lines for IVM showed cor-
relation coefficients ≥0.99. The mean recoveries of IVM from plasma
and skin were 76 and 91%, respectively. The precision of the analytical
method of IVM showed a CV of 6% and 4% for plasma and skin, re-
spectively. The limit of quantification in plasma and skin was estab-
lished at 0.2 ng/mL or g.
2.4. Pharmacokinetic and statistical analysis of the data
The plasma and skin concentrations vs. time curves obtained after
each treatment in each individual animal were fitted with the PK
Solutions 2.0 (Ashland, Ohio, USA) computer software. The area under
the concentration vs. time curves (AUC) was calculated by the trape-
zoidal rule (Gibaldi and Perrier, 1982). IVM plasma concentrations and
the pharmacokinetic parameters are reported as mean ± SEM. Corre-
lation between individual plasma and skin IVM concentrations was
performed by parametric analysis (Pearson’s r).
Mean IVM concentrations in plasma and skin and pharmacokinetic
parameters were statistically compared using ANOVA. The assumption
that the data obtained after treatments have the same variance was
assessed. A Kruskal Wallis test was used where significant differences
among standard deviations were observed. A value of P< 0.05 was
considered statistically significant. The statistical analysis was per-
formed using the Instat 3.0 Software (Graph Pad Software, CA, USA).
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Parasite scores were calculated and expressed as mean ± SEM. For
each treatment, each animal served as its own control and the different
scores were compared using Friedman test. Kruskal Wallis test was used
to compare the scores obtained after different treatments. Based on
cured animals in treated groups, the efficacy was calculated according
to the following formula (Losson and Lonneux, 1996):
Efficacy (%) from day 0 to day× = (Total number of treated
cattle− number of cattle still infected on day x/total number of treated
cattle) × 100.
3. Results
3.1. Pharmacological assay
IVM was detected in plasma and skin of all treated animals. Both
commercial formulations showed similar levels of IVM plasma con-
centrations. Mean IVM concentrations for both formulations were be-
tween 22.5 and 2.8 ng/mL after single administration on day 0 (Groups
1 and 3) and between 44 and 6 ng/mL after the administration of IVM
on days 0 and 7 (Groups 2 and 4). The comparative IVM plasma con-
centrations after the administration of both formulations are shown in
Fig. 1. The repeated administration of both IVM formulations at day 0
and 7 (Groups 2 and 4) accounted for greater plasma drug concentra-
tions resulting in higher IVM concentrations between 14 and 28 days
post-treatment compared with the single administration (P < 0.05).
The mean AUC in plasma after the repeated administration of IVM was
between 1.65 (Formulation A) and 2 (Formulation B) fold greater than
those obtained after the single treatment.
IVM was well distributed from the plasma to the skin without sig-
nificant differences between both formulations. There was a positive
correlation between IVM concentrations in skin and plasma (r:
0.73 P < 0.0001). The mean ratios between IVM availabililty (mea-
sured as AUC) in the skin and in plasma were between 1.2 and 2.1. The
double administration of IVM increased significantly the IVM con-
centrations in the skin of areas affected by mange. The concentrations
of IVM in the skin are compared in Fig. 2. Comparative mean IVM
plasma and skin availability (measured as AUC) for formulations A and
B are shown in Table 1.
3.2. Parasitological observations
IVM failed to achieve a parasitological cure in the different groups
of animals affected by mange. The failure was observed with both
formulations (A and B) administered as single or repeated treatment. At
the beginning of the trial, P. ovis density scores were between 3.8 and
4.3. A significant decrease in P. ovis density scores was observed at 21
and 28 days post-treatment following the single IVM treatment, and at
14, 21 and 28 days post-treatment in the animals having received the
repeated administration. Based on the number of animals cured, the
range of efficacy was between 0% on day 7 and 60% on day 28 post-
treatment. No significant differences in the P. ovis density scores were
observed after the treatment with both formulations as single or re-
peated injections The scores and the efficacies of the different treat-
ments against P. ovis are shown in Table 2.
The pharmacokinetic-pharmacodynamic relationship for IVM was
evaluated using the plasma systemic exposure (measured as AUC) and
the time (days) during which IVM plasma concentrations were above
15 ng/mL (T > 15). These pharmacological parameters were related
with the individual efficacy against mites (density score). The mean
AUC and T > 15 in the animals that were negative at day 28 (density
score 0) were significantly greater (P < 0.05) than those observed in
the positive animals having mites counts> 1 (Fig. 3).
4. Discussion
Psoroptic mange is a highly relevant parasitic disease that affects
mainly beef cattle and leads to marked economic losses (Lonneux et al.,
1998). The combination of stress factors related to Psoroptic mange may
increase the maintenance energy requirements of calves, even when P.
Fig. 1. Comparative mean (± SEM) (n= 8) ivermectin (IVM) plasma con-
centrations obtained after the subcutaneous administration (single and re-
peated treatments) of the formulations A and B to cattle naturally infected with
Psoroptes ovis.
Fig. 2. Comparative mean (± SEM) (n=8) ivermectin (IVM) skin concentra-
tions obtained after the subcutaneous administration (single and repeated
treatments) of the formulations A and B to cattle naturally infected with
Psoroptes ovis.
Table 1
Comparative mean (± SEM) (n= 8) ivermectin (IVM) plasma and skin ex-
posure (measured as AUC) obtained after the subcutaneous administration
(single and repeated treatments) of the formulations A and B to cattle naturally
infected with Psoroptes ovis.
TREATMENT Plasma
AUC
(ng·d/mL)
Skin
AUC
(ng·d/g)
Ratio
AUC Skin/AUC
Plasma
Formulation A (single
treatment – day 0)
355 ± 25a 429 ± 50a 1.22 ± 0.14a
Formulation B (single
treatment – day 0)
300 ± 30a 587 ± 75a 2.10 ± 0.32a
Formulation A (repeated
treatment – days 0 and 7)
586 ± 83b 812 ± 122b 1.42 ± 0.11a
Formulation B (repeated
treatment – days 0 and 7)
618 ± 65b 980 ± 158b 1.70 ± 0.29a
Different letters between rows show significant differences at P < 0.05.
AUC: area under the concentration vs. time curve between the moment of drug
administration and day 28 following administration.
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ovis infestations are low (Cole and Guillot, 1987). Besides, infestations
covering 30% of the body area have been shown to reduce the daily
weight gain (Cole et al., 1984). Among the drugs available to control
Psoroptic mange, IVM was widely chosen due to its excellent efficacy
against P. ovis in cattle (Campbell and Benz, 1984). Many studies have
reported that a single subcutaneous injection of IVM completely elim-
inates mite populations. However, the drug takes several days to be-
come effective, and it does not kill all population of mites until 14 days
after treatment (Guillot and Meleney, 1982). The physicochemical and
pharmacokinetics features of IVM support its high efficacy against P.
ovis. Due to its high lipophilicity, IVM shows a long persistence and a
wide distribution from plasma to different tissues of parasite location
which is essential for its activity against different parasites (Lifschitz
et al., 2000).
In the current trial, IVM was detected in plasma from day 0 to day
28 post-administration. The repeated treatment at days 0 and 7 (Groups
2 and 4) accounted for a significantly higher systemic availability
compared with that obtained after the single administration (Table 1).
The distribution of IVM to the skin layers is relevant to achieve an
optimal efficacy against P. ovis. Previous work has shown a strong
correlation between plasma and skin concentrations of IVM after its
subcutaneous injection to healthy cattle (Lifschitz et al., 2000). The
ratio between IVM availability in the skin and plasma was determined
as 1.45 (Lifschitz et al., 2000). The current work measures for the first
time the relationship between plasma and skin concentrations of IVM in
cattle affected by mange. This issue is very important as the in-
flammatory process and hyperkeratosis that exist in animals affected by
P. ovis may lead to changes in the pattern of IVM distribution to the
skin. In the current trial, IVM was widely distributed to the skin. Al-
though the concentrations of IVM in skin correlated to those observed
in plasma, the coefficient of correlation was lower (0.73) compared
with that previously reported in healthy animals (0.99) (Lifschitz et al.,
2000). The relationship between skin and plasma availability was be-
tween 1.22 and 2.10, values that are in the same range than those
observed in healthy calves (Lifschitz et al., 2000).
In this study, IVM failed to cure infected animals in contrast with a
number of previous assays (Benz et al., 1989; Lonneux et al., 1997). In
some cases, a repeated injection of IVM is needed in order to obtain an
optimal efficacy, especially when animals suffer from hyperkeratosis
and the drug is suspected to have more difficulties to reach the parasites
(Vercruysse and Rew, 2002). Our study demonstrated high drug levels
in the skin of affected animals, especially after the double injection of
IVM. Therefore, the phamacokinetics should be discarded as the reason
behind therapeutic failure. Although the density score of mites sig-
nificantly decreased on day 28 post-treatment, the efficacy obtained
after the administration of both IVM formulations as single or repeated
treatments was between 30 and 60% (Table 2). Few reports on the
failure of IVM treatment against P. ovis in cattle have been published
(Genchi et al., 2008; Lekimme et al., 2010). In one of them, two
treatments with a generic IVM formulation given at a 14-day interval
failed to cure five out of eight Blue Belgian cattle and therefore a po-
tential development of resistance was suspected (Lekimme et al., 2010).
In another trial, although similar plasma kinetics disposition profiles
were observed between the reference and generic formulations, only
the animals treated with the pioneering pharmaceutical product were
completely negative after two doses of IVM on days 0 and 8 (Genchi
et al., 2008). In the current trial, the pioneer and the generic
Table 2
Efficacy of ivermectin (IVM) obtained after the subcutaneous administration (single and repeated treatments) of the formulations A and B to cattle naturally infected
with Psoroptes ovis: mean density scores (± SEM) and percentage of cured animals.
MEAN SCORE (% Efficacy)
TREATMENT Day 0 Day 7 Day 14 Day 21 Day 28
Formulation A
(single treatment – day 0)
4.1 ± 0.3a (0) 3.6 ± 0.5a (0) 2.6 ± 0.5a (10) 1.5 ± 0.6b (40) 1.4 ± 0.4b (40)
Formulation B
(single treatment – day 0)
4.1 ± 0.3a (0) 3.3 ± 0.5a (0) 2.5 ± 0.6a (10) 2.0 ± 0.7a (30) 0.9 ± 0.4b (50)
Formulation A
(repeated treatment – days 0 and 7)
4.3 ± 0.3a (0) 3.0 ± 0.5a (10) 2.6 ± 0.6a (20) 2.1 ± 0.6b (30) 1.1 ± 0.3b (30)
Formulation B
(repeated treatment – days 0 and 7)
3.8 ± 0.3a (0) 2.8 ± 0.4a (0) 0.9 ± 0.3b (50) 0.8 ± 0.2b (30) 0.4 ± 0.2b (60)
Density scores: 0: no mites; 1: 1–5 mites; 2: 6–25 mites; 3: 26–50 mites; 4: 51–100 mites; 5 > 100 mites.
Different letters between columns (days post-treatments) show significant differences compared with the density score obtained at day 0 (P < 0.05).
The values in brackets show the percentage of parasitologically cured animals at each day post-treatment.
Fig. 3. Pharmacokinetic-pharmacodynamic relationship for ivermectin (IVM)
against Psoroptes ovis: a) comparative mean plasma systemic exposure (mea-
sured as AUC) and b) time (days) during which IVM plasma concentrations
were above 15 ng/mL (T > 15) obtained in the negative animals at day 28
post-treatment (density score 0) and in the positive animals with mites
counts> 1. (*) Mean values are significantly different (P < 0.05).
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formulation showed equivalent IVM concentrations in plasma and skin
of infected animals. Both formulations showed similar kinetics dis-
position profiles after the single and the repeated injection of IVM
(Figs. 1 and 2, Table 1). However, both treatment protocols failed to
control mange infections and animals in all of the experimental groups
had living mites on day 28 post-treatment. The intensive use of IVM
during the last 30 years, which in the Tandil area chiefly aims at con-
trolling gastrointestinal parasites, could have exerted a selection pres-
sure on mites towards resistance to IVM. Thus, failures in efficacy ob-
served in the current trial may be due to the development of mite
resistance against IVM. Recently, the treatment failure of sheep scab in
United Kingdom has been associated to acquired resistance of P. ovis
against ML. In this case, the lack of susceptibility of mites was corro-
borated in vitro (Doherty et al., 2018)
The characterization of the pharmacokinetic-pharmacodynamic re-
lationship is relevant to optimize the use of antiparasitic compounds.
This information is not usually available as the in vitro assays use ex-
tremely high concentrations compared with those observed in vivo.
Lifschitz et al. (2000) suggested that 1 ng/g was the minimal drug
concentration necessary to achieve an optimal efficacy against suscep-
tible gastrointestinal nematodes. Based on this minimal IVM con-
centration, the period of time post-treatment during which IVM remains
effective was estimated. In the case of ticks and other ectoparasites, the
exposure to the drug following IVM injection occurs during feeding and
therefore its persistence directly influences drug uptake and efficacy
(Jackson, 1989). To achieve an efficacy of 99% against Rhipicephalus
microplus, a minimal plasma concentration of 8 ng/mL during the whole
tick development period (21 days) is considered appropriate (Davey
et al., 2010). There is no similar information concerning P. ovis. Taking
into account the efficacy and kinetics data, we hypothesized that 15 ng/
mL was the threshold plasma concentration necessary to cure animals
infected with the particular P. ovis isolate involved in the current trial.
The time above this minimal concentration was also calculated. The
T > 15 was significantly longer in the animals without parasite counts
(14.9 days) compared with the animals exhibiting living mites on day
28 (10.3 days) (Fig. 3). The AUC in the animals with a density score of 0
at day 28 post-treatment was significantly greater (40%) compared
with positive animals (Fig. 3). These preliminary data on the pharma-
cokinetic-pharmacodynamic relationship for the activity of IVM against
P. ovis reinforce the relevance of the level and the length of drug ex-
posure above the threshold for obtaining an optimal efficacy. Further in
vivo and in vitro evaluations are needed to establish an accurate re-
lationship between IVM concentrations and drug efficacy against P.
ovis.
In Argentina, a low number of cattle mange outbreaks were re-
ported for many years, mainly due to the intensive use of IVM to control
gastrointestinal nematodes. However, veterinarians have reported an
increase in mange infection cases in the last few years, as well as failure
in the efficacy of IVM to control clinical outbreaks. Due to the high
animal density and stress conditions, feedlots provide the ideal en-
vironment for mange development. The current trial reported for the
first time failures of the efficacy of IVM against P. ovis. in Argentina,
involving pharmacological records and parasitological observations.
Although both commercial formulations showed a similar plasma ki-
netic disposition and high drug distribution to the skin, the level of drug
exposure was not sufficient to cure the infected steers after both single
and repeated administration of IVM. Additional studies are needed to
confirm the presence of resistant strains of P. ovis and to establish ap-
propriate measures to control the disease.
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